BDSX - Biodesix Inc

https://www.biodesix.com

Momentum: Bearish

Recent News

Biodesix Announces One-for-Twenty Reverse Stock Split

GlobeNewswire • 4 days, 3 hours ago • score: 0.01

LOUISVILLE, Colo., Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. ( Nasdaq: BDSX ) ( "Biodesix" or the "Company" ) , a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split ( the "Reverse Stock Split" ) of the Company's common stock, par value $0.001, ...

Bullish

Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth ( BIG9 ) Conference

GlobeNewswire • 1 week, 3 days ago • score: 0.62

LOUISVILLE, Colo., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. ( Nasdaq: BDSX ) , a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets' 9th Annual Best Ideas Growth ( BIG9 ) ...

Bullish

Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth ( BIG9 ) Conference - Biodesix ( NASDAQ:BDSX )

Benzinga • 1 week, 3 days ago • score: 0.61

LOUISVILLE, Colo., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. BDSX, a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets' 9th Annual Best Ideas Growth ( BIG9 ) Conference on ...

Bullish

Biodesix Stock Surges Over 51% Overnight After Jack Schuler's $1.5M Share Purchase Revealed - Biodesix ( NASDAQ:BDSX )

Benzinga • 1 week, 4 days ago • score: 0.26

Biodesix Inc. BDSX shares jumped 51.64% to $0.64 in after-hours trading on Wednesday, following disclosure of a substantial insider purchase by major shareholder Jack W. Schuler. Check out the current price of BDSX stock here.

Bullish

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence ( COE ) for NGS Diagnostics

GlobeNewswire • 3 weeks, 6 days ago • score: 0.37

Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer ...

Neutral

Biodesix, Inc. ( BDSX ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire • 1 month, 1 week ago • score: 0.54

BOULDER, Colo., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. ( Nasdaq: BDSX ) , a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings ...

Bullish

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference - Biodesix ( NASDAQ:BDSX )

Benzinga • 1 month, 1 week ago • score: 0.51

BOULDER, Colo., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. BDSX, a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.

52W High

$1.88

52W Low

$0.17

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.00

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.72

EV/Revenue (<3 favorable)

1.52

P/S (TTM) (<3 favorable)

0.85

P/B (<3 favorable)

56.88

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

54.51%

Institutions (25–75% balanced)

24.32%

Shares Outstanding

146,633,000

Float

58,552,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

76,556,000

Gross Profit (TTM)

60,301,000

EPS (TTM)

-0.26

Profit Margin (>10% good)

-0.54%

Operating Margin (TTM) (higher better)

-0.48%

ROE (TTM) (>15% strong)

-2.20%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.12

Momentum

Bearish momentum

Value

0.0098

0.0191

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025